Audit 24284

FY End
2022-12-31
Total Expended
$50.79M
Findings
0
Programs
58
Year: 2022 Accepted: 2023-06-12
Auditor: Moss Adams LLP

Organization Exclusion Status:

Checking exclusion status...

Findings

No findings recorded

Programs

ALN Program Spent Major Findings
93.855 Allergy and Infectious Diseases Research $30.21M Yes 0
93.837 Cardiovascular Diseases Research $2.26M Yes 0
93.855 Consortium for Hiv/aids Vaccine Development $2.00M Yes 0
93.396 Cancer Biology Research $1.91M Yes 0
93.846 Arthritis, Musculoskeletal and Skin Diseases Research $1.02M Yes 0
93.393 Cancer Cause and Prevention Research $990,124 Yes 0
93.395 Cancer Treatment Research $899,225 Yes 0
93.353 21st Century Cures Act - Beau Biden Cancer Moonshot $873,493 Yes 0
93.855 Airway Inflammation and Airway Remodeling $866,570 Yes 0
93.394 Cancer Detection and Diagnosis Research $762,566 Yes 0
93.837 Immunophenotyping for Precision Medicine for Cardiovascular Disease in People Living with Hiv $731,372 Yes 0
93.839 Neutrophil Lineage in Inflammation $697,027 Yes 0
93.859 Biomedical Research and Research Training $687,942 Yes 0
93.855 Triple Humanized Ace2-Tmprss-Fcgrt Mouse Models for Covid Research in the C57bu6 and Balbic Backgrounds $616,749 Yes 0
93.855 Discovering Durable Pan-Coronavirus Immunity $572,669 Yes 0
93.853 Autoimmune Features of Neurodegenerative Disorders $531,116 Yes 0
93.855 Aids Clinical Trials Group for Research on Therapeutics for Hiv and Related Infections $407,475 Yes 0
93.855 Immune Engineering of Optimized Sequential Immunization Strategies for Hiv Vaccines $404,154 Yes 0
93.394 Sars-Cov-2 Correlates of Protection in A Latin-Orgin Population $372,015 Yes 0
93.855 Structure-Guided Design of Broadly Neutralizing Lassa Virus Bispecific Antibodies $371,593 Yes 0
93.839 Cell Adhesion Mechanisms in Vascular Disease & Thrombosis $353,309 Yes 0
93.855 Transcription Factor Regulation of Cd4 and Cd8 T Cell Effector and Memory Differentiation and Function $323,909 Yes 0
93.855 Childhood Asthma in Urban Settings Clinical Research Network (cause) Leadership Center $284,357 Yes 0
93.855 Protective Immunity Following Dengue Virus Natural Infections and Vaccination $265,150 Yes 0
93.866 The Microvascular Aging and Eicosanoids Women's Evaluation of Systemic Aging Tenacity (mae-West) - ("you Are Never Too Old to Become Younger!") Specialized Center for Research Excellence (score) $217,240 Yes 0
93.837 Immunologic, Inflammatory, and Clinical Contributors to Hiv-Related Heart Failure with Preserved Ejection Fraction (hepef) $190,773 Yes 0
93.855 Fusion Peptide Directed Immunogens That Elicit Neutralizing and Protective Antibodies in Non-Human Primates $172,935 Yes 0
93.855 Rationally Designed Pan-Ebolavirus Vaccine $164,637 Yes 0
93.855 Semantic Integration of Protein Epitopes and Functional Features for Infectious and Autoimmune Disease Knowledge Discovery $136,015 Yes 0
93.847 Diabetes, Digestive, and Kidney Diseases Extramural Research $118,819 Yes 0
93.837 Vaccine Induced Immune-Inflammatory Response and Cardiovascular Risk $118,621 Yes 0
93.855 Genetics Linkage in Lupus $111,910 Yes 0
93.121 Head and Neck Cancer Neoantigen Characterization and Therapeutic Targeting $104,014 Yes 0
93.855 Emerging Infections: Surveillance, Epidemiology and Pathogenesis $101,537 Yes 0
93.172 Non-Destructive Epigenetic Sequencing with Dna Deaminase Enzymes $96,392 Yes 0
93.855 B and T Cell Biology of Protection From and Eradication of Siv/shiv Infection $89,224 Yes 0
93.310 Trans-Nih Research Support $85,079 Yes 0
93.242 The Role of Trio Signaling in Neuronal Development, Synaptic Function, and Circuit Connectivity $74,187 Yes 0
93.855 Design and Testing of Germline-Targeting and Boosting Immunogens to Elicit 10e8-Like Broadly Neutralizing Antibodies Against Hiv $73,055 Yes 0
93.394 Diversity and Determinants of the Immune-Inflammatory Response to Sars-Cov-2 $72,705 Yes 0
47.074 Mechanisms of A Natural Bacterial Biosensor Using Rt-Dna $72,693 Yes 0
93.397 Specialized Cancer Center Core Support Grant $66,359 Yes 0
93.855 The Development and Evaluation of Pan-Coronavirus Vaccines $58,268 Yes 0
93.855 Structure-Based Design of Novel Lassa Virus Glycoproteins for Vaccine Development $57,116 Yes 0
93.395 Combining Irreversible Electroporation with Immunotherapy for the Systemic Treatment of Pancreatic Cancer $38,737 Yes 0
93.855 Targeting of Somatic Hypermutation in the Genome $27,730 Yes 0
93.855 Structural, Functional, and Mechanistic Analysis of Autoreactive Cd8 T Cells $24,851 Yes 0
93.838 San Diego Team Asthma Management Using Phenotypes (stamp) $22,545 Yes 0
93.855 Identifying Individuals at Risk of Progression to Activate Tuberculosis $22,093 Yes 0
93.837 Molecular Regulation of Atherosclerosis $20,109 Yes 0
93.855 Histamine-Releasing Factor in Leap Peanut Allergy $18,451 Yes 0
93.393 A Rational Systematic Approach to Find Combinations of Pharmacologic and Immune Therapies That Target Identifiable Oncogenic States $16,286 Yes 0
93.855 Ige Antibody Responses to the Oligosaccharide Galactose-Alpha-1,3-Galactose (alphagal) in Murine and Human Atherosclerosis $15,728 Yes 0
93.855 Mechanism and Regulation of V(d)j Recombination $3,022 Yes 0
93.398 Cancer Research Manpower $702 Yes 0
93.242 Mechanisms Regulating Incrna Short and Long Range Signaling $-3,630 Yes 0
93.853 Molecular Basis of Zika-Induced Microcephaly $-27,533 Yes 0
93.855 4-(aminomethyl) Benzamides As Novel Anti-Ebola Agents $-32,104 Yes 0

Contacts

Name Title Type
ZPAUY3FQMM26 Victoria Kern Auditee
8587526557 Scott Simpson Auditor
No contacts on file

Notes to SEFA

Title: Note 1 Basis of Presentation Accounting Policies: Note 2 Summary of Significant Accounting Policies Expenditures reported on the Schedule are reported on the accrual basis of accounting. Such expenditures are recognized following the cost principles contained in the Uniform Guidance, wherein certain types of expenditures are not allowed or are limited as to reimbursement. Negative amounts shown on the Schedule represent adjustments or credits made in the normal course of business to amounts reported as expenditures in prior years. De Minimis Rate Used: N Rate Explanation: Note 3 Indirect Cost Rate The Institute has elected not to use the 10 percent de minimus indirect cost rate as allowed under Uniform Guidance. The accompanying schedule of expenditures of federal awards (the Schedule) includes the federal award activity of La Jolla Institute for Immunology (the Institute) under programs of the federal government for the year ended December 31, 2022. The information in this Schedule is presented in accordance with the requirements of Title 2 U.S. Code of Federal Regulations Part 200, Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards (Uniform Guidance). Because it presents only a selected portion of the operations of the Institute, it is not intended to, and does not, present the financial position, changes in net assets, or cash flows of the Institute.